Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05005975




Registration number
NCT05005975
Ethics application status
Date submitted
28/07/2021
Date registered
16/08/2021
Date last updated
13/03/2024

Titles & IDs
Public title
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Scientific title
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Secondary ID [1] 0 0
jRCT2041210146
Secondary ID [2] 0 0
MT-7117-A-301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
EPP 0 0
XLP 0 0
Condition category
Condition code
Skin 0 0 0 0
Other skin conditions
Blood 0 0 0 0
Other blood disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MT-7117

Experimental: Dersimelagon 200mg -


Treatment: Drugs: MT-7117
MT-7117
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of patients with Treatment emergent adverse events (TEAEs) (including serious adverse events [SAEs] and adverse events of special interest [AESIs]).
Timepoint [1] 0 0
up to 30 further months
Primary outcome [2] 0 0
Number of patients with abnormal Physical examination data
Timepoint [2] 0 0
up to 30 further months
Primary outcome [3] 0 0
Number of patients with Nevi appearance
Timepoint [3] 0 0
up to 30 further months

Eligibility
Key inclusion criteria
- 1. Subjects provided written informed consent to participate. For adolescent subjects,
both adolescent assent and parental consent will be provided.

- 2. Subjects who complete MT-7117-G01 (complete through Week 58 [Visit 12])

- 3. Subjects have a body weight of =30 kg.

- 4. Subjects are willing and able to travel to the study sites for all scheduled
visits.

- 5. In the Investigator's opinion, subject can understand the nature of the study and
any risks involved in participation, and is willing to cooperate and comply with the
protocol restrictions and requirements (including travel).

- 6. Female subjects who are non-lactating and have a negative urine pregnancy test at
baseline visit prior to receiving the first dose of study drug.

- 7. Female subjects of childbearing potential and male subjects with partner of
childbearing potential must agree to use 2 effective methods of contraception
including barrier method (especially for female subjects, one method must be highly
effective method)
Minimum age
12 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
A subject will NOT be eligible for this study if ANY of the following criteria apply:

- 1. History or presence of photodermatoses other than EPP or XLP.

- 2. Presence or history of any hepatobiliary disease at Screening, determined as
clinically significant by the Investigator after the discussion with the Sponsor
Medical Monitor.

- 3. Subjects with AST, ALT, ALP =3.0 × upper limit of normal (ULN) or total bilirubin
>1.5 × ULN at Screening.

- 4. Subjects with or having a history (in the last 2 years) of excessive alcohol intake
in the opinion of the Investigator.

- 5. History of melanoma.

- 6. Presence of melanoma and/or lesions suspicious for melanoma at Screening.

- 7. History of familial melanoma (defined as having 2 or more first-degree relatives,
such as parents, sibling and/or child).

- 8. Presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin
lesions. Any suspicious lesions or nevi will be evaluated. If the suspicious lesion or
nevi cannot be resolved through biopsy or excision, the subject will be excluded from
the study.

- 9. History or presence of psychiatric disease judged to be clinically significant by
the Investigator and which may interfere with the study evaluation and/or safety of
the subjects.

- 10. Presence of clinically significant acute or chronic renal disease based upon the
subject's medical records including hemodialysis; an estimated glomerular filtration
rate (eGFR) <60 mL/min/1.73m2 as calculated by the CKD-EPI creatinine equation (2009)
for adults and by the Schwartz creatinine equation for adolescents (2009). MDRD can be
used for adults per local recommendations.

- 11. Presence of any clinically significant disease or laboratory abnormality which, in
the opinion of the Investigator, can interfere with the study objectives and/or safety
of the subjects.

- 12. Female subjects who are pregnant, lactating, or intending to become pregnant
during the study.

- 13. Treatment with phototherapy or afamelanotide within 3 months before baseline
(Visit 2).

- 14. Treatment with cimetidine or antioxidant agents at doses which, in the opinion of
the Investigator, may affect study endpoints (including but not limited to
beta-carotene, cysteine, pyridoxine) within 4 weeks before baseline (Visit 2).

- 15. Chronic treatment with any scheduled analgesic agents including, but not limited
to opioids and opioid derivatives such as morphine, hydrocodone, oxycodone, fentanyl,
or their combination with other unscheduled analgesics or non-steroidal
anti-inflammatory drug (Percocet and Vicodin-like prescription drugs) within 4 weeks
before baseline (Visit 2). Acute use of scheduled narcotics greater than 3 months
prior to baseline, over-the-counter medications (OTCs), such as non-steroidal
anti-inflammatory drugs (NSAIDs) or aspirin for analgesia, or prior temporary use of
scheduled agents within 3 months of baseline (Visit 2) are not excluded.

- 16. Treatment with any drugs or supplements which, in the opinion of the Investigator,
can interfere with the objectives of the study or safety of the subjects.

- 17. Previous treatment with any investigational agent other than dersimelagon within
12 weeks before Screening OR 5 half-lives of the investigational product (whichever is
longer).

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/08/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2025
Actual
Sample size
Target
151
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Wesley Medical Research - Brisbane
Recruitment hospital [2] 0 0
Royal Melbourne Hospital (RMH) - Parkville
Recruitment postcode(s) [1] 0 0
4066 - Brisbane
Recruitment postcode(s) [2] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Massachusetts
Country [3] 0 0
United States of America
State/province [3] 0 0
Missouri
Country [4] 0 0
United States of America
State/province [4] 0 0
New York
Country [5] 0 0
United States of America
State/province [5] 0 0
North Carolina
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio
Country [7] 0 0
United States of America
State/province [7] 0 0
Pennsylvania
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
United States of America
State/province [9] 0 0
Washington
Country [10] 0 0
Canada
State/province [10] 0 0
Alberta
Country [11] 0 0
Germany
State/province [11] 0 0
Berlin
Country [12] 0 0
Italy
State/province [12] 0 0
Brescia BS
Country [13] 0 0
Italy
State/province [13] 0 0
Milan
Country [14] 0 0
Italy
State/province [14] 0 0
Modena
Country [15] 0 0
Italy
State/province [15] 0 0
Rome
Country [16] 0 0
Japan
State/province [16] 0 0
Hyogo
Country [17] 0 0
Japan
State/province [17] 0 0
Ishikawa
Country [18] 0 0
Japan
State/province [18] 0 0
Osaka
Country [19] 0 0
Japan
State/province [19] 0 0
Tokyo
Country [20] 0 0
Japan
State/province [20] 0 0
Toyama
Country [21] 0 0
Norway
State/province [21] 0 0
Bergen
Country [22] 0 0
Spain
State/province [22] 0 0
Barcelona
Country [23] 0 0
Spain
State/province [23] 0 0
Madrid
Country [24] 0 0
Sweden
State/province [24] 0 0
Stockholm
Country [25] 0 0
United Kingdom
State/province [25] 0 0
MN
Country [26] 0 0
United Kingdom
State/province [26] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Mitsubishi Tanabe Pharma America Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To evaluate the long-term safety and tolerability of oral dersimelagon.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05005975
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Head of Medical Science
Address 0 0
Mitsubishi Tanabe Pharma America Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05005975